Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
204 stopped studies mapped to Malignant Bladder Neoplasm and descendants · 91% state a reason
Over the 204 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04688931 | A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder…(ATLAS) | Phase 3 | terminated | Dec 30, 2020 | UroGen Pharma Ltd. | Alternate approach pursued | Other (stated, no rule matched) |
| NCT05643690 | Urine Sample Collection for Validation of the AnchorDx UriFind™ Bladder Cancer Assay | — | suspended | Dec 9, 2022 | AnchorDx Medical Co. Ltd. US | Protocol amendment. | Other (stated, no rule matched) |
| NCT05699135 | A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People… | — | terminated | Jan 26, 2023 | Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety and/or… | Safety / toxicity |
| NCT06301308 | A Novel Application of 2% Lidocaine Injection for Male Rigid cycstoscopy-a… | Phase 3 | withdrawn | Mar 8, 2024 | Second Xiangya Hospital of Central South University | The standard measures of anaesthesia in cystoscopy are not uniform internationally, and given this,… | Enrollment / accrual |
| NCT04806334 | Radiogenomics of Muscle Invasive Bladder Cancer | N/A | terminated | Mar 19, 2021 | Cedars-Sinai Medical Center | Slow accrual | Enrollment / accrual |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | Phase 1 | terminated | Sep 29, 2021 | Pfizer | The study was terminated by the Sponsor due to business decision and not due to any safety concerns… | Safety / toxicity |
| NCT03909893 | A Study of Adaptive Radiation Therapy for Pelvic Genitourinary Cancer(ARTGU) | N/A | withdrawn | Apr 10, 2019 | University Health Network, Toronto | This study is being closed. The protocol may be reviewed and consolidated under a new study… | Other (stated, no rule matched) |
| NCT05335707 | Longitudinal Geriatric Assessment to Optimize Outcomes of Older Patients With… | — | withdrawn | Apr 19, 2022 | University of Kansas Medical Center | Study funds ended on 7/31/2023 | Funding |
| NCT04779489 | Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer(CIRTiN-BC) | N/A | terminated | Mar 3, 2021 | University of Texas Southwestern Medical Center | Study was closed to low accrual. | Enrollment / accrual |
| NCT05363605 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | Phase 1 / Phase 2 | terminated | May 6, 2022 | Fusion Pharmaceuticals Inc. | Fusion announced that it is discontinuing this study as part of a portfolio prioritization and… | Sponsor / business decision |
| NCT02887248 | Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or… | Phase 2 | terminated | Sep 2, 2016 | SCRI Development Innovations, LLC | Enrollment issues | Enrollment / accrual |
| NCT01215136 | First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced… | Phase 2 | terminated | Oct 6, 2010 | Matthew Galsky | Lack of Accrual | Enrollment / accrual |
| NCT04602117 | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine… | Phase 1 | withdrawn | Oct 26, 2020 | QuantumLeap Healthcare Collaborative | Study withdrawn as scientific interest in pursuing the SYD985+Paclitaxel combination has diminished. | Other (stated, no rule matched) |
| NCT04054752 | Vaccine Response With NT-I7 | Phase 1 | withdrawn | Aug 13, 2019 | National Cancer Institute (NCI) | No subjects enrolled. | Enrollment / accrual |
| NCT05120622 | Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High…(Rideau) | Phase 1 / Phase 2 | withdrawn | Nov 15, 2021 | University of British Columbia | Withdrawal of funding | Funding |
| NCT06069453 | Hyaluronic Acid Sodium Salt and Hydeal-D in the Management of LUTS After TURBT for NMIBC. | N/A | terminated | Oct 5, 2023 | Fidia Farmaceutici s.p.a. | Sponsor decision | Sponsor / business decision |
| NCT03912818 | Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant… | Phase 2 | terminated | Apr 11, 2019 | Stanford University | Difficulty with enrollment | Enrollment / accrual |
| NCT04066894 | Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal… | Phase 2 | terminated | Aug 26, 2019 | M.D. Anderson Cancer Center | Due to Issues Enrolling Patients | Enrollment / accrual |
| NCT00352079 | BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer | Phase 3 | terminated | Jul 14, 2006 | NCIC Clinical Trials Group | terminated due to poor accrual | Enrollment / accrual |
| NCT04424641 | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid… | Phase 1 / Phase 2 | terminated | Jun 11, 2020 | Genmab | Study was terminated due to MTD was reached | Other (stated, no rule matched) |
| NCT05568407 | A Study of Avelumab in Real-World Treatment for Patients With Advanced or Metastatic… | — | terminated | Oct 5, 2022 | Pfizer | The trial terminated due to the inability to recruit the planned number of subjects. The decision… | Safety / toxicity |
| NCT03552796 | sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer | Phase 1 | withdrawn | Jun 12, 2018 | University of Southern California | Budget issues | Funding |
| NCT03397394 | Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma(ATLAS) | Phase 2 | terminated | Jan 12, 2018 | pharmaand GmbH | Efficacy did not meet the continuance criteria and DMC recommended to stop enrollment. | Efficacy / futility |
| NCT03637803 | Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors | Phase 1 / Phase 2 | terminated | Aug 20, 2018 | 4D pharma plc | Sponsor insolvency | Other (stated, no rule matched) |
| NCT05259397 | PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle… | Phase 1 | withdrawn | Feb 28, 2022 | Pfizer | Pfizer has decided to terminate Study C4661001 due to strategic considerations. This decision is… | Safety / toxicity |
| NCT05221827 | Clinical Performance Evaluation of the C2i-Test | — | terminated | Feb 3, 2022 | C2i Genomics | Not in line with company's recently updated clinical development strategy | Sponsor / business decision |
| NCT05052372 | Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving… | — | terminated | Sep 22, 2021 | xCures | Sponsor request to terminate study due to enrollment numbers | Enrollment / accrual |
| NCT04127318 | Low-moderate Intensity Pedaling During Immunotherapy Administration | N/A | withdrawn | Oct 15, 2019 | Rush University Medical Center | lack of resources | Other (stated, no rule matched) |
| NCT05395260 | FL- 101 Study in Non-Metastatic MIBC | Early Phase 1 | withdrawn | May 27, 2022 | Flame Biosciences | Sponsor Decision | Sponsor / business decision |
| NCT02735512 | MDSC Clinical Assay in Finding and Monitoring Cancer Cells in Blood and Urine Samples… | — | terminated | Apr 12, 2016 | University of Southern California | Insufficient accrual | Enrollment / accrual |
| NCT04972253 | Phase I BLASST-3 Trial((BLASST)-3) | Phase 1 | withdrawn | Jul 22, 2021 | Guru P. Sonpavde | Low Accrual | Enrollment / accrual |
| NCT02901548 | Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial… | Phase 2 | terminated | Sep 15, 2016 | H. Lee Moffitt Cancer Center and Research Institute | Study closed early due to futility | Efficacy / futility |
| NCT01732107 | Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression | Phase 2 | terminated | Nov 22, 2012 | Noah Hahn, M.D. | Development of dovitinib was stopped. | Other (stated, no rule matched) |
| NCT03839472 | Continuous Bladder Irrigation Following Transurethral Resection of Bladder Tumors | N/A | withdrawn | Feb 15, 2019 | Case Comprehensive Cancer Center | Revision to improve cell recovery | Other (stated, no rule matched) |
| NCT03718741 | Prospective Study of Adjuvant Radiotherapy in High Risk Bladder Cancer.(Bladder-Aid) | N/A | terminated | Oct 24, 2018 | Istituto Clinico Humanitas | few patients enrolled | Enrollment / accrual |
| NCT02164942 | LCI-GU-BLA-SPEC-001: Aurora Kinase Expression in Muscle-Invasive Bladder Cancer | — | terminated | Jun 17, 2014 | Wake Forest University Health Sciences | Futility | Efficacy / futility |
| NCT03266900 | A Superiority Trial to Compare Re-resection of High-grade T1 Bladder Urothelial Carcinoma…(RESECT) | Early Phase 1 | terminated | Aug 30, 2017 | University Health Network, Toronto | Difficulties with accrual | Enrollment / accrual |
| NCT05260788 | Mapping 3D Bladder | — | withdrawn | Mar 2, 2022 | University Health Network, Toronto | Administrative issues. | Other (stated, no rule matched) |
| NCT03549650 | Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms | Phase 2 | terminated | Jun 8, 2018 | Sir Mortimer B. Davis - Jewish General Hospital | Given the updated precautions on Elmiron as well as the risk benefit profile, we have decided to… | Other (stated, no rule matched) |
| NCT01954173 | Adjuvant Radiation for High Risk Bladder Cancer | N/A | terminated | Oct 1, 2013 | Emory University | Slow accrual | Enrollment / accrual |
| NCT01126749 | Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus… | Phase 1 / Phase 2 | terminated | May 20, 2010 | Eisai Inc. | Study was terminated as per sponsor's decision | Sponsor / business decision |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | Phase 1 | terminated | Dec 11, 2015 | MacroGenics | Business decision (not for safety reasons) | Safety / toxicity |
| NCT02767921 | sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or… | Phase 1 | terminated | May 11, 2016 | University of Southern California | Insufficient accrual | Enrollment / accrual |
| NCT02792192 | Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille… | Phase 1 / Phase 2 | terminated | Jun 7, 2016 | Hoffmann-La Roche | The study was terminated early as the study had met its goals of providing preliminary safety and… | Safety / toxicity |
| NCT02563561 | A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing… | Phase 3 | terminated | Sep 30, 2015 | Spectrum Pharmaceuticals, Inc | not stated | Not stated |
| NCT04273724 | Early Intervention for Impairments Identified During Comprehensive Geriatric Assessment… | N/A | terminated | Feb 18, 2020 | UNC Lineberger Comprehensive Cancer Center | Investigator left and research was discontinued. | Investigator |
| NCT04280640 | Relationship Between Circulating Tumor Cell Cultures' Treatment Response and Clinical… | — | withdrawn | Feb 21, 2020 | UNC Lineberger Comprehensive Cancer Center | PI left UNC. | Investigator |
| NCT03224182 | A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants… | Phase 3 | terminated | Jul 21, 2017 | Spectrum Pharmaceuticals, Inc | Suspended development | Other (stated, no rule matched) |
| NCT04579133 | Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for… | Phase 2 | terminated | Oct 8, 2020 | Latin American Cooperative Oncology Group | Not approved | Other (stated, no rule matched) |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in… | Phase 1 / Phase 2 | withdrawn | Jul 9, 2020 | NKGen Biotech, Inc. | Trial not initiated | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jun 6, 2024source: clinicaltrials